About

Dr. Mikael Dolsten has served as an Agilent director since September 2021 and is a member of the Audit and Finance Committee. Since March 2025 he has been Founding CEO and Chairman of Quarry Thera, LLC, after serving as President of Worldwide Research, Development and Medical, Chief Scientific Officer and Executive Vice President of Pfizer, Inc. from 2010 to January 2025. He has held earlier research-leadership roles at Wyeth, Boehringer Ingelheim and AstraZeneca, and currently serves on the board of Rocket Pharmaceuticals, Inc.

Roles

Agilent Technologies, Inc.
Director · Current role
September 2021–present
Quarry Thera, LLC
Founding CEO and Chairman of the Board
March 2025 - present
Pfizer, Inc.
President of Worldwide Research, Development and Medical, Chief Scientific Officer and Executive Vice President
2010 - January 2025
Wyeth Pharmaceuticals, Inc.
Senior Vice President; President, Wyeth Research
2008 - 2009
Boehringer Ingelheim
Executive Vice President, Head of Pharma Research
Orbimed Advisors, LLC
Private Equity Partner

External Roles

Rocket Pharmaceuticals, Inc.
Director
September 2024 - present

Director Compensation

FY 2025
Cash retainer
$115,000
ComponentBoard and committee cash retainers earned in FY2025
Stock awards
$220,426
ComponentAnnual stock grant, ASC 718 grant-date fair value (1,819 shares)
Total
$335,426

Also at Agilent Technologies, Inc.

Related

See how VectorShift works for your firm

Request Demo